Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions
International Journal of Eating Disorders · 2026-11 · 59 (11) · 2375-2388
DOI: 10.1002/eat.70164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Eating Disorders, online erschienen am 02.07.2026. Verfasst von Elena Koning und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Feeding and Eating Disorders, Psilocybin, Hallucinogens, Mental Disorders. Die Arbeit nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Eating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the implications for alternative nosological frameworks, trial design, and clinical care.
Method
A narrative review was conducted synthesizing clinical, mechanistic, and conceptual literature on PT for EDs and common psychiatric comorbidities. Searches of academic databases were supplemented by hand‐searching and clinical trial registries. Thematic synthesis focused on transdiagnostic clinical evidence, mechanistic theories, and implications for the Hierarchical Taxonomy of Psychopathology (HiTOP), Research Domain Criteria (RDoC), treatment development, and clinical trial design.
Results
Preliminary clinical evidence supports the feasibility, safety, and therapeutic effects of PT for EDs, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms (i.e., serotonergic receptor agonism, psychoplastogenic effects, neural network desynchronization) target shared vulnerabilities that map onto dimensional constructs in HiTOP (Emotional Dysfunction superspectrum, Internalizing spectrum) and RDoC (negative/positive valence, cognitive, and social process domains) nosologies. Future research should explore pragmatic trial designs and dimensional outcome measures to capture the real‐world complexities of PT for EDs.
Discussion
PT demonstrates transdiagnostic therapeutic potential for EDs, and the advancement of dimensional nosologies, complex intervention frameworks, and personalized treatment protocols may address existing gaps in research and clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
- Nova Scotia Health, Halifax, Nova Scotia, Canada.
- School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Elena Koning, Jérémie Richard, Aaron Keshen
Zitieren
APA
Koning, E., Richard, J., & Keshen, A. (2026). Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions. International Journal of Eating Disorders, 59(11), 2375-2388. https://doi.org/10.1002/eat.70164
Vancouver
Koning E, Richard J, Keshen A. Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions. International Journal of Eating Disorders. 2026;59(11):2375-2388. doi:10.1002/eat.70164
BibTeX
@article{Koning2026,
author = {Koning, Elena and Richard, Jérémie and Keshen, Aaron},
title = {Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions},
journal = {International Journal of Eating Disorders},
year = {2026},
volume = {59},
number = {11},
pages = {2375--2388},
doi = {10.1002/eat.70164}
}
EUVIMED